The US FDA has approved GSK’s Hibsago for chronic hepatitis B, with 19% of trial participants achieving a functional cure.

Shanghai, China - October 16, 2026 - MicroPort Scientific Corporation announced that it and its associated companies have reached a cumulative total of 50 products accepted into China's National ...

Oral olorofim was non-inferior to AmBisome® followed by standard of care (AmBisome®+SOC), with Day 42 all-cause mortality of 23.8% for olorofim ...

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up ...

$2,220,000 of JOHNSON & JOHNSON SERVICES INC lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act ...

Time takes on a different meaning for each of these women. For national foil fencer Amita Berthier, it is measured in the minutes and seconds that can reverse the course of a bout. Designer Fock ...

One of the most representative products from Hengrui Pharma's ADC research and development platform, trastuzumab rezetecan is being developed for more than ten indications, including breast, lung, ...

Dr. Norah Terrault, Chief of Gastroenterology & Hepatology, USC Keck Medical Center, said: “This is the start of a new era in treating people living with CHB. Bepirovirsen offers patients the ...

Some of the most worthwhile changes cost little, while others only pay off when they address a specific weakness in your ...

Eloxx Pharmaceuticals said it has finalised the design of its planned global clinical trial in autosomal dominant polycystic kidney disease (ADPKD) following discussions with regulatory authorities ...

Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to ...

Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB) Approval based on phase III data ...